Biogen piles on more long-term Aduhelm data, linking biomarker to Alzheimer’s clinical benefit
Despite a disastrous commercial rollout, Biogen is still producing longer-term data for beleaguered Alzheimer’s disease therapy Aduhelm.
In patients who’ve been t...